MDxHealth (NASDAQ:MDXH – Get Free Report) and BioXcel Therapeutics (NASDAQ:BTAI – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, institutional ownership, earnings, profitability and dividends.
Profitability
This table compares MDxHealth and BioXcel Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MDxHealth | -33.46% | N/A | -24.25% |
| BioXcel Therapeutics | -9,549.87% | N/A | -185.82% |
Earnings and Valuation
This table compares MDxHealth and BioXcel Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MDxHealth | $107.88 million | 0.28 | -$33.52 million | ($0.72) | -0.83 |
| BioXcel Therapeutics | $640,000.00 | 3.63 | -$69.90 million | ($3.79) | -0.02 |
MDxHealth has higher revenue and earnings than BioXcel Therapeutics. MDxHealth is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current recommendations and price targets for MDxHealth and BioXcel Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MDxHealth | 1 | 1 | 3 | 0 | 2.40 |
| BioXcel Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
MDxHealth presently has a consensus target price of $2.17, indicating a potential upside of 261.17%. BioXcel Therapeutics has a consensus target price of $11.00, indicating a potential upside of 14,744.80%. Given BioXcel Therapeutics’ higher probable upside, analysts plainly believe BioXcel Therapeutics is more favorable than MDxHealth.
Insider & Institutional Ownership
30.7% of BioXcel Therapeutics shares are owned by institutional investors. 1.7% of MDxHealth shares are owned by company insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Risk & Volatility
MDxHealth has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Comparatively, BioXcel Therapeutics has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500.
Summary
MDxHealth beats BioXcel Therapeutics on 8 of the 13 factors compared between the two stocks.
About MDxHealth
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
About BioXcel Therapeutics
BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Receive News & Ratings for MDxHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDxHealth and related companies with MarketBeat.com's FREE daily email newsletter.
